We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





MeMed Highlights Pioneering Blood Test for Accurately Distinguishing Between Bacterial and Viral Infection

By LabMedica International staff writers
Posted on 26 Apr 2022

MeMed (Haifa, Israel) hosted an integrated symposium, oral presentation and poster spotlighting MeMed BV at the 32nd European Congress of Clinical Microbiology and Infectious Diseases Conference (ECCMID) in Lisbon, Portugal, April 23-26, 2022. More...

Clinical key opinion leaders presented clinical use and performance data in scientific sessions, including an integrated symposium, oral abstract presentation and poster abstract on MeMed BV performance validation data.

MeMed BV is a pioneering blood test to help physicians with the seemingly simple clinical dilemma - does a patient have a bacterial or viral infection. The test harnesses the power of the body’s immune system and delivers results in just 15 minutes. MeMed BV measures and computationally integrates the levels of three immune system proteins: TRAIL, IP-10 and CRP. MeMed BV is the only test for distinguishing bacterial from viral infections that has been validated in multinational, double-blind and external clinical studies. The clinical studies demonstrating the diagnostic performance of MeMed BV encompassed thousands of patients and are published in high impact medical journals.

Unlike most conventional solutions that seek to detect bacteria or viruses, MeMed BV is an advanced host response test that uses the human immune system as the disease sensor. This approach offers unique advantages far beyond speed and accuracy: (i) It can diagnose cases when the infection site is not readily accessible or is unknown (e.g., pneumonia or fever without source) because immune markers circulate throughout the body; (ii) It can prevent false alarms due to detection of bacteria or viruses that are mere bystanders and are not causing the disease; (iii) It is robust to rapidly evolving pathogens. The MeMed BV test runs on MeMed Key, a cutting edge, compact immunoassay platform that is accurate and easy to use, making it possible to conduct highly sensitive, rapid, multiplexed protein measurements that previously could only be done on expensive central lab equipment.

Related Links:
MeMed 


New
Gold Member
Latex Test
SLE-Latex Test
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
Unstirred Waterbath
HumAqua 5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.